**Histopathological spectrum of prostatic lesions in correlation with prostate specific antigen and prognostic significance of prostate specific antigen in comparison with histological grade of prostatic adenocarcinoma – A Hospital based study.**

**Abstract:-**

**Background:-**

Prostate gland disease causes significant morbidity in elderly males. Our objective of the study was to evaluate the histopathological spectrum of prostatic lesions in correlation with prostate specific antigen and compare the prostate specific antigen with histological grade of prostatic adenocarcinoma.

**Methods:-**

The present retrospective study was carried in the department of pathology, Narayana Medical College & Hospital, Nellore, and Andhra Pradesh, India from January 2015 to December 2015. 119 Prostatic biopsy specimens were analyzed histopathologically for diagnosis of types of prostatic lesion and correlated with serum PSA level. Prostatic adeno carcinomas

**1**

were graded according to Gleason histological grading. Gleason’s grading of tumors was correlated with serum PSA levels

**Result:-**

Out of 119 patients, 95 cases had benign prostatic hyperplasia, 17 cases had prostatic adenocarcinoma, 7 cases had prostatitis.

In our study, the maximum number of BPH cases (51.58%) showed PSA levels < 4ng/ml.Most of prostatic adenocarcinoma (82.35%) displayed PSA levels >10ng/ml. 5 cases (71.43%) of prostatitis showed PSA levels of 4-10ng/ml.Maximum cases of grade 2 and grade 3 prostatic adenocarcinoma had PSA range of 20-49 .99ng/ml.

**Conclusion:**

Benign prostatic hyperplasia is the most commonly diagnosed prostatic lesions. Investigation like serum PSA level detection can aid in the diagnosis, but accurate diagnosis of non-neoplastic and neoplastic lesions of prostate can be made by histopathological study of prostate biopsy. There is a positive relation was seen between higher levels of PSA and Gleason histopathological grade.

**2**

**Keywords:**

Prostate specific antigen, Gleason histopathological grade, Prostatic adeno carcinoma, prostatic lesions

**Introduction:**

Recent reports around the globe suggest that prostate gland disease causes significant morbidity and mortality in elderly male1. In USA, it has been recorded as the important cause of cancer-related deaths in men after lung cancer. Among the total population, one out of six will be diagnosed with prostate cancer during lifetime. Annual checkup of Prostatic specific antigen levels in the men above 50 years of age was recommended by American cancer society2, 3. For the diagnosis of prostatic cancer, PSA acts as an important tumor marker 4. For every gram of malignant tissue, the PSA levels rised by 2-3ng/dl which is 10 times more when compared to rise in PSA level for every gram of hyper plastic tissue5, 6. Frequently encountered prostatic lesions are Benign Prostatic Hyperplasia, chronic prostatitis, granulomatous prostatitis and Adenocarcinoma1. Our main aim of this study was to evaluate the

3

histopathological spectrum of prostatic lesions in correlation with PSA levels and prognostic significance of PSA levels by comparing with histopathological grade of prostatic adeno carcinoma.

**Materials and methods:-**

1. The present retrospective study was carried in the department of pathology, Narayana Medical College & Hospital, Nellore, Andhra Pradesh, during the period of January 2015 to December 2105.Samples (serum and biopsy) from 119 patients, aged between 35 to 84 years, were examined for the level of serum PSA and histopathology of prostate biopsy was studied.
2. Serum PSA was done on CHEMI-LUMINESCENCE IMMUNOASSAY on ACCESS-2 (BECKMAN COULTER) by chemiluminescence method. The range of PSA determination using this equipment is 0.1-150ng/ml. Prostatic biopsy was collected from patients who underwent transurethral resection of the prostate for BPH, open

4

Prostatectomy for prostatic lesion and transrectal ultrasound guided biopsy for suspicious malignancy.

1. Prostatic biopsy specimens were kept in 10% neutral buffered formalin. Specimens were grossly examined for size/quantity and weight followed by processing, paraffin embedding and section cutting. 3-5 microns section were stained with Hematoxylin & Eosin and reported. Prostatic adenocarcinomas were graded according to Gleason’s histopathological grade.

**Statistical analysis:-**

* Data collected was entered in MS Excel and analyzed using SPSS-Version 22.0.Percentages and chi-square values were calculated.
* A P value of 0.05 was taken as significance.

**5**

**Results:**

During the period of one year from January 2015 to December 2015, 119 prostatic biopsy specimens were received. The age ranges of patients were 31-90 years. The mean age of presentation was 64.46±10.70 years. Most common prostatic lesion is BPH [95 cases (79.83%)] with mean age 63.67±11.29 years. Second most common lesion is prostatic adenocarcinoma [17 cases (14.28%)] with mean age 68.88±6.49 years and least common is prostatitis [7 cases (5.88%)] with mean age 64.43±7.03 years (Figure1).

In our study of 24 cases of prostatic lesions, 3 cases were prostatic adenocarcinomas, 19 cases BPH and 2 cases were prostatitis and occurred in the age group of 51-60 years. In the Age group of 61-70 years they were 45 cases of prostatic lesions, out of which 7 were prostatic adenocarcinomas, 34 were BPH and 4 cases were chronic prostatitis (Figure 3& 4). The age group of 71-80 years they were 35 cases of prostatic lesions, out of which 7 were prostatic adenocarcinomas, 27 were BPH and One case were Prostatitis.

6

In our study 49 cases (51.58%) of BPH shows PSA levels < 4 ng/ml, 41 cases (43.16%) of BPH shows PSA levels of 4-10ng/ml and 5 cases (5.26%) of BPH shows PSA levels of >10ng/ml. 14 cases (82.35%) of prostatic adenocarcinoma shows PSA levels of >10ng/ml, One case (5.88%)of prostatic adenocarcinoma shows PSA levels of < 4 ng/ml and 2cases (11.76%)of prostatic adenocarcinoma shows PSA levels of 4-10ng/ml . 5 cases (71.43% ) of prostatitis shows PSA levels of 4-10ng/ml and 2 cases of prostatitis shows PSA levels of <4 ng/ml.PSA levels are higher in prostatic adeno carcinoma when compared to BPH and protatitis and this difference is statistically significant (p=0.000) (Table1).

PSA levels in prostatic carcinoma were compared with Gleason’s histopathological grade of the tumors. Maximum number of prostatic adenocarcinoma were in grade 2 [12 cases (70.59%)].Maximum cases of grade 2 and grade 3 prostatic adenocarcinomas had PSA range of 20-49.49ng/ml. One case (5.88%) of grade 2 adenocarcinoma had PSA range of 0-3.98ng/ml .One case (5.88%) of grade 1 and one case (5.88%) of grade 2 adenocarcinoma had

7

PSA range of 4-9.99ng/ml.4 Cases (23.53%) of grade 2 prostatic adenocarcinoma had PSA range of 50- 99.99ng/ml.In our study there is a difference in PSA levels across the grades which is statistically significant (p=0.043)(Table 2 ).

**Discussion:**

The prostate is a pear - shaped glandular organ that weighs up to 20g in the normal adult male and it has been divided into anterior, middle, posterior and two lateral lobes by drawing divergent lines from the centrally located urethra. The prostate can be divided into four biological and anatomical zones, peripheral zone, central zone, transitional zone and periurethral gland regions. The transitional zone and periurethral regions are the exclusive sites of origin of nodular hyperplasia, whereas the peripheral zone is the one most susceptible to prostatitis and carcinoma. The glandular component of the organ is composed of acini and ducts, the latter subdivided into large (primary, major, excretory) and peripheral (secretory, minor). Both acini and ducts contain secretory cells, basal cells and scattered neuroendrocine cells. The secretory cells which

**8**

are located in the luminal side of the gland, contribute a wide variety of products of the seminal fluid. They produce prostatic acid phosphate (PAP) and prostate specific antigen (PSA). PSA is glycoprotein that has been identified as a kallikrein like protease.

In the present study most common lesion is BPH (Figure 2) with mean age 63.67±11.29 and BPH is more common between 51-80 years of age. Prostatic adenocarcinoma (Figure 5) is second most common lesion in our study. Prostatic adenocarcinoma mean age is 68.88±6.49 and more common between 61to 80 years of age in this study. In our study prostatic adenocarcinoma mean age figure are comparable with finding from other studies which report the mean age of 69 years by Thompson IM et al7, mean age of 65 years by Lyn et al8 ,and mean age of 68 years by H A Mwakyoma et al9 .

In the present study BPH cases are 79.83% which is nearby comparable with Kshitij et al10, Jeven et al12, Arun chitale et al13 and Janardan et al13 studies. In our study prostatic adenocarcinoma incidence was 14.28% which is

9

nearby comparable with Jevan et al12 and Arun Chitale et al13 studies (Table 3)

In our study BPH cases are most commonly present between PSA level 0-4.0ng/ml (51.58%) Which is compared with study of Khitij et al10, and prostatic adenocarcinoma cases are more commonly present with PSA level >10.0ng/ml (82.35%) and it is nearly compared with H.A M Walyoma et al9 Kshitij et al10and Sladana Zivkovic et al15 studies (Table 4).

In the present study we evaluated the prognostic importance of serum PSA levels with grades of adenocarcinoma prostate. In our study maximum number of malignancies (58.82%) has serum PSA value of more than 20 ng/ml which coincided with study done by Sladana Zivkovic etal15 study (52.25%) and lower than Shanthi V etal16 study (80.95%). 2 cases (11.76%) of prostatic adeno carcinoma was detected with PSA values in the range of 4-9.99ng/ml which is higher than the Shanthi Vetal16 study (4.76%) and lower than the Sladana Zivkovic etal15 study (27.5%).4 cases of(23.53%) prostatic adeno carcinoma was detected with PSA values in the range of 10-19.99ng/ml which is higher than the

10

Sladana Zivkovic etal15 study (17.5%) and Shanthi V etal16 study (14.29%) (Table 5).

In the present study, one case (5.88%) of grade 2 prostatic adeno carcinoma was noted with serum PSA range of 0-3.99ng/ml.One case (5.88%) of grade 1 prostatic adeno carcinoma are noted with serum PSA range of 4-9.99ng/ml which is slightly higher than Shanthi Vetal16 study (4.76%) . One case (5.88%) of grade 2 prostatic adeno carcinoma . 3 cases(17.65%) of grade 2 prostatic adeno carcinoma were noted with serum PSA range of 10-19.99ng/ml which is higher than the Shanthi V etal16 study (11.9%) .One case (5.88% ) of grade 3 prostatic adeno carcinoma , 3 cases (17.65%) of grade 2 prostatic adeno carcinomas were noted with serum PSA range of 20-49.99ng/ml which is slightly higher than Shanthi V etal16 study (16.67%). 3 cases (17.65%) of grade 3 prostatic adeno carcinoma , 4 cases of (23.53%)of grade 2 prostatic adeno carcinoma were noted with serum PSA range of 50-99.99ng/ml which is similar to Shanthi V etal16 study (23.8%).In our study histopathological grade 2 prostatic adeno

11

carcinoma were restricted to PSA levels of 10ng/ml and above ,but grade 1 prostatic adeno carcinomas was restricted to PSA levels of < 10ng/ml and grade 3 carcinomas were not having any correlation with specific PSA levels (Table 6).

In studies done by Shanthi V et al 16 (2012-2015)and Lennox Anderson Jackson et al 157(2012), histopathological grade 3 adeno carcinomas had a PSA range of 50-149.99ng/ml and 76-190 ng/ml respectively .Our study coincided with the conclusion drawn from the studies of Shanthi V et al 15(2012-2015) and Lennox Anderson Jackson et al 17(2012) that histological higher grades of prostatic carcinomas are associated with higher PSA levels.

**Conclusion:**

Benign prostatic hyperplasia was the most frequent lesion encountered followed by adenocarcinoma prostate .Prostatic adenocarcinomas were associated with raised prostate specific antigen more than 10ng/ml. In our study, there was a positive relation between higher levels of serum PSA and Gleason’s

12

histopathological grade of prostatic adenocarcinoma. But poorly differentiated prostatic adeno carcinomas (higher grade) did not show correlation with serum PSA levels indicating that as the tumor becomes poorly differentiated, tumor cell production of PSA is reduced.

**Acknowledgement:-**

The authors are thankful to the Miss.D.PADMAJA B.tech and all the faculty of department of pathology, Narayana Medical College and Hospital, Nellore.

**References:**

1. Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: a histologic study with PSA correlation. Nigerian postgrad Med J. 2011; 8(2); 98-104. [PubMed]

2. Denis LJ.Diagnosing benign prostate hyperplasia versus prostate cancer.Br J Urol 1995:75(suppl) 17-23

3.Akdas A.Turkan T,Turkeil,Cerviki,Biren T and Gurmen N.The diagnostic accuracy of digital rectal examination ,transrectal

13

ultrasonography,prostate specific antigen (PSA) density in prostate carcinoma.Br J Urol 1995:76:54-6

4. Radiae S.Prostate cancer molecular staging. State of the Art in prostate and breast cancer treatment. European school of Oncology. Advanced course. September, 2002: Education boo.2000.p.101-4.

5. Stamey TA, Yang N, hay AR, Mc Neal JE, Frina Fs, and Red wine E.Prostate specific antigen as a serum marker for adeno carcinoma of the prostate.N Engl J Med.1987:317:909-16

6. Walsh pc.Why make an early diagnosis of prostate cancer.J Urol 1990:147:853-4

7.Thompson IM,Pauler DK,Goodmann PJ,etal.Prevalence of prostate cancer among men with a prostate specific antigen level=4.0ng/ml.Journal of Medicine .2004:350(22):2239-2246.

8.Lyn NNk,Collins GN,Alex Ak et al.A comparative analysis of the role of prostate specific antigen parameters in clinical practice. The Prostate Journal 2000:2(4):205-210

14

9. H A Mwaakyoma et al correlation of Gleason”” score and pretreatment prostate specific antigen in patients. Professional Med J Jun 2010; 17(2):235-240.

10. Kshitij A.jyoti sapre, A.s.Agnihotri et al: utility of prostate specific antigen in different prostatic lesion: pathology and laboratory medicine: June 2011; vol 3 issue 1:18-23.

11. Azmi A Haroun, Azmi S.Hadidy, Ziad M.Awwad et al: utility of free PSA serum level and its related parameters in the diagnosis of prostate cancer. Soudi journal of kidney diseases and transplantation.2011:22(2)291-297.

12. Djavan B optimal predictors of prostate cancer on repeat prostate biopsy; a prospective study of 1051 men .Journal of urology (UNITED STATES) Apr 2000; 163(4) p1144-8.

13. Dr.Janardan V.Bhatt, Dr.Jayashree M.shah &Dr.Falguni R.shah prostate –Assessment to management 2008.

14. Ishtiaq Ali Khan, Muhammad nasir e Tal: carcinoma of prostate in clinically benign enlarged gland; J Ayub med coll Abottabad 2008; 20(2) p90-92

15

15. Sladana Zivkovic et al: correlation prostate specific antigen and histopathological difference of prostate carcinoma; arch oncol 2004; 12(3)148-51.

16. Shanthi V et al. prognostic importance of prostate specific antigen in assessing histological grade of prostatic adenocarcinoma.Int J Med Res Rev 2015; 3(3):268-272.

17. Lennox Anderson Jackson et al. Donovan A McGrowder, Ruby Alexander-Lindo.Prostate Specific antigen and Gleason Score in men with prostate cancer at a private Diagnostic radiology centre in Western Jamaica, Asian Pacific journal of cancer prevention ,vol 13,2012,1453-1456.

16

**Figures and Legends**

Figure: 1 Pie chart showing percentage of BPH, Prostatic Adenocarcinoma and Prostatitis.

Figure: 2 photomicrograph showing benign prostatic hyperplasia (H&E, 100X)

Figure: 3 photomicrograph showing chronic prostatitis (H&E, 100X)

Figure: 4 Photomicrograph showing granulomatous prostatitis (H&E, 100X)

Figure: 5 Photomicrograph showing prostatic adenocarcinoma with Gleason grading score (4+4=8) [H&E, 400X].

**17**

**Table: 01 Histopathology diagnosis related with range of Prostate Specific antigen level:**

|  |  |  |  |
| --- | --- | --- | --- |
| **PSA** | **Adenocarcinoma** | **BPH** | **Prostatitis** |
| 0-4.0ng/ml | 1(5.88%) | 49(51.58%) | 2(28.57%) |
| 4-10.0ng/ml | 2(11.76%) | 41(43.16%) | 5(71.43%) |
| 10-20ng/ml | 4(23.53%) | 5(5.26%) | 0 |
| >20ng/ml | 10(58.82%) | 0 | 0 |
| Total | 17(100%) | 95(100%) | 7(100%) |

P=0.000 significant

PSA level are higher in prostate adeno carcinoma when compared to BPH & prostatitis and this difference is statistically significant (P=0.000).

**18**

**Table: 02 Correlation between serum PSA levels and Gleason grade of prostactic adeno carcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
| **PSA Range(ng/ml)** | **Grade1** | **Grade 2** | **Grade3** |
| 0-3.99 | 0 | 1(5.88%) | 0 |
| 4-9.99 | 1(5.88%) | 1(5.88%) | 0 |
| 10-19.99 | 0 | 3(17.65%) | 1(5.88%) |
| 20-49.99 | 0 | 3(17.65%) | 3(17.65%) |
| 50-99.99 | 0 | 4(23.53%) | 0 |
| Total (no=17) | 1(5.88%) | 12(70.59%) | 4(23.53%) |

There is a difference in PSA levels across the grades and this is statistically significant (P=0.043).

**19**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **s.no** | **Histopathological Diagnosis** | **Kshitij**  **et al10** | **Azmi .A**  **Haroun et al11** | **Jevan**  **et al12** | **Arun chitale**  **et al13** | **Janardan**  **et al13** | **Present study** |
| 1 | BPH | 85.8% | 64.48% | 83% | 89% | 93.9% | 95(79.83%) |
| 2 | Prostatic adenocarcinoma | 8.35% | 27.1% | 17% | 11% | 6.06% | 17(14.28%) |
| 3. | Prostatitis | 0.64% | 8.4% | - | - | - | 7(5.88%) |

**Table: 03 Comparison between different**

**types of lesion with other studies**

**20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **PSA range** | **BPH** | | | **Malignant prostatic lesion** | | | |
| **(ng/ml)** | **Kshitij et al10** | **Ishtiaq Ali**  **Khan et al14** | **Present study** | **Kshitij**  **et al10** | **H.A Mwalyoma**  **et al9** | **Sladana**  **Zivkovic**  **et al15** | **Present**  **study** |
| 0-4.0 | 71.6% | - | 51.58% | 10.5% | - | 2.50% | 5.88% |
| 4-10.0 | 22.6% | 85% | 43.16% | 26.3% | 5.3% | 27.50% | 11.76% |
| >10 | 3% | 15% | 5.26% | 63.15% | 94.7% | 70.0% | 82.35% |

**Table: 04 Benign and malignant prostatic lesion: Comparison between Prostate Specific Antigen level with other studies**

**21**

**Table: 05 Comparison between our study and other studies in relation to PSA levels and Prostatic adenocarcinoma.**

|  |  |  |  |
| --- | --- | --- | --- |
| **PSA levels (ng/ml)** | **Sladana Zivkovic et al 15(2004)** | **Shanthi.V etal16(2012-2015)** | **Our study(2015)** |
| 0-3.99 | 1(2.5%) | 0 | 1(5.88%) |
| 4-9.99 | 11(27.5%) | 2(4.76%) | 2(11.76%) |
| 10-19.99 | 7(17.5%) | 6(14.29%) | 4(23.53%) |
| >20 | 21(52.25%) | 34(80.95%) | 10(58.82%) |

**22**

**Table: 6 Comparison between our study and Shanthi v etal16 study in relation to serum PSA levels and Gleason grade of prostatic adeno carcinoma.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **PSA levels (ng/ml)** | **Grade 1** | | **Grade 2** | | **Grade 3** | |
| **Shanthi V etal16** | **Our study** | **Shanthi V etal16** | **Our study** | **Shanthi V etal16** | **Our study** |
| 0-3.99 | 0 | 0 | 0 | 1(5.88%) | 0 | 0 |
| 4-9.99 | 2(4.76%) | 1(5.88%) | 0 | 1(5.88%) | 0 | 0 |
| 10-19.99 | 0 | 0 | 5(11.9%) | 3(17.65%) | 0 | 1(5.88%) |
| 20-49.99 | 0 | 0 | 7(16.67%) | 3(17.65%) | 0 | 3(17.65%) |
| 50-99.99 | 0 | 0 | 10(23.8%) | 4(23.53%) | 4(9.52%) | 0 |
| 100-149.99 | 0 | 0 | 7(16.67%) | 0 | 2(4.76%) | 0 |
| 150-199.99 | 0 | 0 | 0 | 0 | 0 | 0 |
| >200 | 0 | 0 | 5(11.9%) | 0 | 0 | 0 |
| **Total** | 2(4.76%) | 1(5.88%) | 34(80.95% | 12(70.59%) | 6(14.29%) | 4(23.53%) |

**23**

Figure 1: Pie chart showing percentage of BPH, Prostatic Adenocarcinoma and Prostatitis.

24



Figure-2

25



Figure-3

26



Figure-4

27



Figure-5

28